IP Library Granted Patent US 12,286,451
Granted Patent B2
US 12,286,451 · App. 17/532,712 · Granted Apr 29, 2025

Borate ester complexes of α-hydroxy carboxylic acids and their conjugate base buffers

Inventor: Mackenzie Shelton (Gretna, VA)
Assignee: MEDTECH PRODUCTS INC.
C07F5/04A61K9/0014
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,286,451
App. No.
17/532,712
Granted
Apr 29, 2025
Kind
B2
Abstract

A composition is provided for use as a buffer in personal care and pharmaceutical formulations. The composition comprises complex esters of boric acid and simple α-hydroxy carboxylic acids, and the corresponding basic conjugate salts of complex esters of boric acid and simple α-hydroxy carboxylic acids. The weight of boric acid and α-hydroxy acid is up to about 1.0% by weight (w/w %) of the composition. The molar ratio of boric acid to α-hydroxy acid is between about 1:1 and about 1:2. The composition may be formulated for topical application. Formulations comprising the composition include a personal lubricant, wound cream, feminine cleansing douche, moisturizing lotion, a wipe, and a cleansing wash. A method of treating the skin is also provided, the method comprising the step of topically applying onto the skin an effective amount of the composition.

Claims (67)

1. A composition for use as a buffer in personal care and pharmaceutical formulations, the composition comprising:

esters of boric acid and α-hydroxy monocarboxylic acids having 2 to 12 carbon atoms; and

corresponding basic conjugate salts of esters of boric acid and α-hydroxy monocarboxylic acids having 2 to 12 carbon atoms, wherein the molar ratio of boric acid to α-hydroxy acid is between about 1:1 and about 1:2, and

wherein the weight of boric acid and α-hydroxy acid is up to about 1.0% by weight (w/w %) of the composition.

2. A composition for use as a buffer in personal care and pharmaceutical formulations, the composition comprising:

esters of boric acid and α-hydroxy monocarboxylic acids having 2 to 12 carbon atoms; and

corresponding basic conjugate salts of esters of boric acid and α-hydroxy monocarboxylic acids having 2 to 12 carbon atoms, wherein the molar ratio of boric acid to α-hydroxy acid is between about 1:1 and about 1:2, and

wherein the weight of boric acid and α-hydroxy acid is up to about 0.5% by weight (w/w %) of the composition.

3. A composition for use as a buffer in personal care and pharmaceutical formulations, the composition comprising:

esters of boric acid and α-hydroxy monocarboxylic acids having 2 to 12 carbon atoms; and

corresponding basic conjugate salts of esters of boric acid and α-hydroxy monocarboxylic acids having 2 to 12 carbon atoms, wherein the molar ratio of boric acid to α-hydroxy acid is between about 1:1 and about 1:2, and

wherein the weight of boric acid and α-hydroxy acid is up to about 0.4% by weight (w/w %) of the composition.

4. A composition for use as a buffer in personal care and pharmaceutical formulations, the composition comprising:

esters of boric acid and α-hydroxy monocarboxylic acids having 2 to 12 carbon atoms; and

corresponding basic conjugate salts of esters of boric acid and α-hydroxy monocarboxylic acids having 2 to 12 carbon atoms,

wherein the molar ratio of boric acid to α-hydroxy acid is between about 1:1.2 and about 1:1.8.

5. A composition for use as a buffer in personal care and pharmaceutical formulations, the composition comprising:

esters of boric acid and α-hydroxy monocarboxylic acids having 2 to 12 carbon atoms; and

corresponding basic conjugate salts of esters of boric acid and α-hydroxy monocarboxylic acids having 2 to 12 carbon atoms,

wherein the molar ratio of boric acid to α-hydroxy acid is between about 1:1.4 and about 1:1.6.

6. A formulation for topical application for use as a personal lubricant, the formulation comprising the composition as recited in claim 1 up to about 1% by weight of the formulation, and further comprising

sodium benzoate up to about 0.50% by weight of the formulation,

xanthan gum up to about 1.0% by weight of the formulation,

hyaluronic acid up to about 0.5% by weight of the formulation, and

aloe vera gel up to about 0.5% by weight of the formulation.

7. The personal lubricant formulation as recited in claim 6 , wherein the composition comprises a boric acid lactic acid ester buffer.

8. A formulation for use as a wound cream, the formulation comprising the composition as recited in claim 1 up to about 1% by weight of the formulation, and further comprising

glycerin up to about 5% by weight of the formulation,

dipalmitoylethyl hydroxyethylmonium methosulfate up to about 3% by weight of the formulation,

emulsifying wax up to about 3.5% by weight of the formulation,

isopropyl myristate up to about 3% by weight of the formulation,

dimethicone up to about 1.25% by weight of the formulation,

cetyl alcohol up to about 2% by weight of the formulation,

lanolin up to about 2% by weight of the formulation, and

potassium chloride up to about 0.35% by weight of the formulation.

9. The wound cream formulation as recited in claim 8 , wherein the composition comprise a boric acid lactic acid ester buffer.

10. A formulation for use as a feminine cleansing douche, the formulation comprising the composition as recited in claim 1 up to about 5% by weight of the formulation, and further comprising

sodium benzoate up to about 1% by weight of the formulation,

edetate disodium up to about 0.5% by weight of the formulation, and

vinegar up to about 0.5% by weight of the formulation.

11. The feminine cleansing douche formulation as recited in claim 10 , wherein the composition comprises a boric acid lactic acid ester buffer.

12. A formulation for use as a moisturizing lotion, the formulation comprising the composition as recited in claim 1 up to about 4% by weight of the formulation, and further comprising

acrylates up to about 0.55% by weight of the formulation,

sunflower seed oil up to about 1% by weight of the formulation,

PEG 40 HCO up to about 0.5% by weight of the formulation,

aminomethyl propanol 2000 up to about 0.9% by weight of the formulation,

sorbitol monolaurate up to about 1% by weight of the formulation,

hemisqualane up to about 2.5% by weight of the formulation, and

phenoxyethanol up to about 0.75% by weight of the formulation.

13. The moisturizing lotion formulation as recited in claim 12 , wherein the acrylates comprise C10-C30 alkyl acrylate crosspolymer.

14. The moisturizing lotion formulation as recited in claim 12 , wherein the composition comprises a boric acid lactic acid ester buffer.

15. A formulation for use as a wipe, the formulation comprising the composition as recited in claim 1 up to about 1.13% by weight of the formulation, and further comprising

decyl glucoside up to about 1% by weight of the formulation,

sodium benzoate up to about 0.5% by weight of the formulation, and

edetate disodium up to about 0.5% by weight of the formulation.

16. The wipe formulation as recited in claim 15 , wherein the composition comprises a boric acid lactic acid ester buffer.

17. A formulation for use as a cleansing wash, the formulation comprising the composition as recited in claim 1 up to about 10% by weight of the formulation, and further comprising

sodium c14-c16 olefin sulfonate up to about 20% by weight of the formulation,

cocamidopropyl hydroxy sultaine up to about 15% by weight of the formulation,

sodium methyl cocoyl taurate up to about 5% by weight of the formulation,

Guar Hydroxypropyl Trimonium Chloride up to about 0.05% by weight of the formulation,

sodium benzoate up to about 1% by weight of the formulation, and

sodium chloride up to about 1% by weight of the formulation.

18. The cleansing wash formulation as recited in claim 17 , wherein the composition comprises a boric acid lactic acid ester buffer.

19. A method of treating the skin comprising the step of topically applying onto the skin an effective amount of the composition as recited in claim 1 .

20. The composition as recited in claim 1 , wherein the composition is in the acidic range of about 3.8-5.8 and the corresponding salts are in the basic range of about 8.2-10.2.

21. The composition as recited in claim 1 , wherein the composition is in the acidic range of about 4.0-5.5 and the corresponding salts are in the basic range of about 8.4-9.9.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED AT REEL: 59941 FRAME: 161. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jan 4, 2025
From: SHELTON, MACKENZIE
To: MEDTECH PRODUCTS INC.
Reel/Frame 069818/0508 →
PATENT SECURITY AGREEMENT (ABL) Recorded Apr 25, 2024
From: DENTEK ORAL CARE, INC.; INSIGHT PHARMACEUTICALS CORPORATION; MEDTECH PRODUCTS INC.
To: CITIBANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 067239/0063 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2022
From: SHELTON, MACKENZIE
To: MEDTECH PRODUCTS, INC.
Reel/Frame 059941/0161 →
Continuity (3)
Provisional Application 63139136 · Jan 19, 2021
Provisional Application 63117166 · Nov 23, 2020
Related Publication 20220162234A1 · May 26, 2022
References Cited (43)
US 5468414A · Panandiker et al. · 1995 [cited by applicant]
US 8920786B2 · Hloucha et al. · 2014 [cited by applicant]
US 9018150B1 · Rizk · 2015 [cited by applicant]
US 10722440B2 · Schroeder et al. · 2020 [cited by applicant]
US 20110166057A1 · Lenoir · 2011 [cited by applicant]
US 20150265528A1 · Shapiro et al. · 2015 [cited by applicant]
US 20160120803A1 · Mathur et al. · 2016 [cited by applicant]
US 20190314258A1 · Laurent et al. · 2019 [cited by applicant]
US 20190365623A1 · Botto · 2019 [cited by applicant]
CA 2137268 · 1993 [cited by applicant]
CA 2128581 · 1995 [cited by applicant]
CA 2208500 · 1996 [cited by applicant]
CA 2543370 · 2004 [cited by applicant]
CA 2583874 · 2006 [cited by applicant]
CA 2709208 · 2009 [cited by applicant]
CA 2208246 · 2009 [cited by applicant]
CA 2414941 · 2010 [cited by applicant]
CA 2398224 · 2011 [cited by applicant]
CA 2793876 · 2011 [cited by applicant]
CA 2494427 · 2013 [cited by applicant]
CA 2633489 · 2013 [cited by applicant]
CA 2730309 · 2014 [cited by applicant]
CA 2883403 · 2014 [cited by applicant]
CA 3000088 · 2017 [cited by applicant]
CA 3026904 · 2017 [cited by applicant]
CA 3047186 · 2018 [cited by applicant]
CA 3057569 · 2018 [cited by applicant]
CA 3060378 · 2018 [cited by applicant]
CA 2916897 · 2019 [cited by applicant]
CA 3086082 · 2019 [cited by applicant]
CA 3096374 · 2019 [cited by applicant]
CA 3017661 · 2020 [cited by applicant]
CN 102993433 · 2015 [cited by applicant]
EP 0742220 · 1999 [cited by applicant]
EP 1372383 · 2008 [cited by applicant]
WO 2004105710 · 2004 [cited by applicant]
WO 2012044416 · 2012 [cited by applicant]
WO 2018191221A1 · 2018 [cited by applicant]
WO 2019030458 · 2019 [cited by applicant]
Larsson, R. and Nunziata, G. “An Infrared Spectroscopic Investigation on the Complexes formed between Boric Acid and Lactic Acid in Aqueous Solution.” Acta Chemica Scandinavica. (1970), vol. 24, pp. 2156-2168. (Year: 19… [cited by examiner]
Pizer, Richard, et al. “The Boric Acid/Lactic Acid System. Equilibria and Reaction Mechanism.” Inorganic Chemistry. (1984), vol. 23, No. 19, pp. 3023-3026. (Year: 1984). [cited by examiner]
Houston, et al., “Tapping Into Boron/ a-Hydroxycarboxylic Acid Interactions in Sensing and Catalysis”, Aust. J. Chem., 2007, 60, 811-815. [cited by applicant]
Houston, et al., “Boric Acid-Catalyzed, Chemoselective Esterification of a-Hydroxycarboxylic Acids”, Organic Letters, Apr. 2004, 5 pages. [cited by applicant]